ENXTPA:SANPharmaceuticals
Sanofi Expands Respiratory Portfolio With Nuvaxovid Role And Lunsekimig Data
Sanofi has become the market authorization holder for Nuvaxovid, a non-mRNA COVID-19 vaccine, in Canada.
The company reported positive phase 2 results for lunsekimig in respiratory conditions including asthma and chronic rhinosinusitis with nasal polyps.
Sanofi (ENXTPA:SAN), trading at €81.02, sits at the center of two fresh respiratory health updates that expand its presence in vaccines and therapeutics. The stock shows a mixed return profile, with a 6.1% gain over the past 30 days and a...